GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss

The unprecedented efficacy of glucagon-like peptide-1 (GLP-1) medications has exposed a gap in how obesity treatment success is measured. According to a study in Clinical Nutrition Open Science, researchers are now calling for a shift away from weight loss alone toward a more complete picture of metabolic quality.¹

“Obesity is driven by a complex interplay of physical, environmental, and psychosocial factors, making it far more than a simple elevation in body mass index,” according to the authors of a study in the Canadian Journal of Physiology and Pharmacology.² “It carries a host of health consequences, including impaired mobility and an increased risk of conditions such as type 2 diabetes (T2D) and cardiovascular diseases.”

When patients experience rapid weight reduction on incretin therapies, up to 20% to 50% of total weight loss can come from fat-free mass. However, fat-free mass includes water, organs, and connective tissue rather than pure skeletal muscle, making muscle quality and functional performance far more important clinical metrics than scale weight alone.^1,3

Skeletal muscle accounts for the majority of insulin-stimulated glucose disposal and plays a central role in maintaining metabolic flexibility and resting energy expenditure. Consequently, evaluating weight-loss quality requires assessing whether metabolically active tissue is preserved during treatment.¹

READ MORE: Individualized Approach Helps When Intensifying GLP-1 Therapy in T2D

Pharmacists occupy a frontline position in translating these biological insights into actionable patient care. At a recent clinical panel, pharmacy experts emphasized that despite medications like semaglutide and tirzepatide offering profound glycemic and cardiovascular benefits, medication management must extend well beyond dispensing prescriptions.⁴

By guiding patients through dosage titration and evaluating individual tolerability, pharmacists help maintain treatment adherence while identifying patients at risk for nutritional deficits or functional decline.

Understanding Body Composition and Muscle Health

A systematic review revealed that although incretin therapies consistently reduce total adiposity and visceral fat, changes in muscle quantity and quality vary substantially across clinical trials. Conventional imaging tools, like dual energy X-ray absorptiometry, often capture changes in non-contractile tissue rather than true muscle deterioration.^3,5

To preserve functional capacity, evidence published in Nutrients recommends that clinicians evaluate muscle strength and physical performance alongside body composition changes. Pharmacists can reinforce these efforts by screening for signs of physical weakness or sarcopenic obesity, particularly among older adults and patients with T2D.⁵

Essential Nutritional and Lifestyle Strategies

Nutritional adequacy serves as a vital pillar in optimizing weight loss quality during GLP-1 therapy. Research indicates that less than half of patients taking GLP-1 receptor agonists reach the recommended protein intake threshold of 1.2 to 1.5 grams per kilogram of body weight daily.^1,2,5

Pharmacists can offer targeted dietary counseling to address early satiety, nausea, and reduced food intake, helping patients prioritize protein-dense foods and essential micronutrients.

Furthermore, integrating progressive resistance exercise 2 to 3 times a week provides the required anabolic stimulus to protect skeletal muscle and maintain bone mineral density during caloric restriction.^2,3,5

Managing Discontinuation and Long-Term Vulnerability

Long-term therapeutic success also requires addressing the biological vulnerability that occurs after treatment discontinuation. A review in eClinicalMedicine found that patients regain approximately 60% of their lost weight within 1 year of stopping GLP-1 therapy, with weight regain eventually plateauing around 75%.^1,6

This rapid rebound highlights the chronic nature of obesity and the necessity of ongoing care. To mitigate weight regain, pharmacists can work alongside multidisciplinary health care teams to implement individualized dose-tapering strategies, monitor cardiometabolic parameters, and educate patients on sustained lifestyle habits.^1,4,6

As novel multi-receptor agonists targeting GLP-1, GIP, and glucagon pathways continue to enter the marketplace, personalized care strategies will become increasingly essential. Pharmacists remain uniquely positioned to empower patients, guide prior authorization workflows, and coordinate longitudinal support across every phase of treatment.^2,4

By refocusing clinical success on metabolic health, pharmacists can ensure that incretin-based therapies deliver durable, holistic benefits.¹

“The available evidence supports a shift from a weight-centric model of obesity treatment toward a more comprehensive framework centered on the quality and sustainability of metabolic adaptation,” concluded the authors of the current study. “High-quality weight loss may emerge as a clinically meaningful endpoint that complements, and potentially redefines, traditional measures of therapeutic success in obesity management.”

READ MORE: Diabetes Resource Center

REFERENCES

1. Luna M, Rodrigues B, Ramalho A. Metabolic determinants of weight-loss quality during and after incretin-based therapies in obesity. Clin Nutr Open Sci. 2026;69:100711. doi:10.1016/j.nutos.2026.100711

2. Moss E, Hawk K, Lollis K, et al. Incretin therapy and obesity: current and future pharmacologic possibilities. Can J Physiol Pharmacol. 2026;104:1-6. doi:10.1139/cjpp-2025-0151

3. Menezes MLL, Chiappa MEG, Kloss RF, et al. Body composition remodelling during GLP‐1‐based therapy: a systematic review and meta‐analysis using a hierarchical physiological framework. Diabetes Obes Metab. August 17, 2026. doi:10.1111/dom.71220

4. Ferruggia K. The pharmacist’s expanding, indispensable role in optimizing GLP-1 management and patient outcomes. Pharmacy Times. 2025;14(5). https://www.pharmacytimes.com/view/the-pharmacist-s-expanding-indispensable-role-in-optimizing-glp-1-management-and-patient-outcomes

5. Šantić R, Martinović L, Pavlović N, et al. Lean mass and musculoskeletal preservation in GLP-1-based obesity treatment: nutrition, exercise, supplementation, and monitoring strategies. Metabolites. 2026 May 27;16(6):364. doi: 10.3390/metabo16060364

6. Budini B, Luo S, Tam M, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. EClinicalMedicine. 2026;93:103796. doi:10.1016/j.eclinm.2026.103796